Further experiments are needed (e.g., combinatorial assays of PI3K inhibitors and NPQ-C6) in order to investigate the potential role of this rapid paradoxical transient AKT activation on the anti-tumor effects of this product in CML. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.